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ABSTRACT
Background
Virus-specific CD8
þ T lymphocytes play a key role in the initial reduction of peak viremia
during acute viral infections, but display signs of increasing dysfunction and exhaustion under
conditions of chronic antigen persistence. It has been suggested that virus-specific CD8
þT cells
with a ‘‘polyfunctional’’ profile, defined by the capacity to secrete multiple cytokines or
chemokines, are most competent in controlling viral replication in chronic HIV-1 infection. We
used HIV-1 infection as a model of chronic persistent viral infection to investigate the process
of exhaustion and dysfunction of virus-specific CD8
þ T cell responses on the single-epitope
level over time, starting in primary HIV-1 infection.
Methods and Findings
We longitudinally analyzed the polyfunctional epitope-specific CD8
þ T cell responses of 18
patients during primary HIV-1 infection before and after therapy initiation or sequence
variation in the targeted epitope. Epitope-specific CD8
þ T cells responded with multiple
effector functions to antigenic stimulation during primary HIV-1 infection, but lost their
polyfunctional capacity in response to antigen and up-regulated programmed death 1 (PD-1)
expression with persistent viremic infection. This exhausted phenotype significantly decreased
upon removal of stimulation by antigen, either in response to antiretroviral therapy or by
reduction of epitope-specific antigen load in the presence of ongoing viral replication, as a
consequence of in vivo selection of cytotoxic T lymphocyte escape mutations in the respective
epitopes. Monofunctionality increased in CD8
þ T cell responses directed against conserved
epitopes from 49% (95% confidence interval 27%–72%) to 76% (56%–95%) (standard deviation
[SD] of the effect size 0.71), while monofunctionality remained stable or slightly decreased for
responses directed against escaped epitopes from 61% (47%–75%) to 56% (42%–70%) (SD of
the effect size 0.18) (p , 0.05).
Conclusion
These data suggest that persistence of antigen can be the cause, rather than the
consequence, of the functional impairment of virus-specific T cell responses observed during
chronic HIV-1 infection, and underscore the importance of evaluating autologous viral
sequences in studies aimed at investigating the relationship between virus-specific immunity
and associated pathogenesis.
The Editors’ Summary of this article follows the references.
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During acute viral infections, antigen-speciﬁc CD8
þ T cells
control viral replication, leading to a clearance or signiﬁcant
reduction of viremia with subsequent development of robust
and fully differentiated memory CD8
þ T cells. However, in
some cases, the immune response is unable to completely
clear a viral infection during acute infection. This inability
leads to viral persistence, which is often associated with the
subsequent development of chronic viral disease. Under
conditions of chronic antigen persistence, virus-speciﬁc CD8
þ
T cells gradually lose their ability to proliferate, to secrete a
diverse proﬁle of cytokines, and they display progressively
dysfunctional cytotoxic activity [1–4], ultimately leading to
exhaustion or even anergy of these cells [5]. The functional
exhaustion of virus-speciﬁc T cells has been best character-
ized in lymphocytic choriomeningitis virus (LCMV) infection
of mice [5–7], and has also been described in several chronic
human infections, such as HIV, hepatitis B virus (HBV), or
hepatitis C virus (HCV) infection [8–10]. Therefore, CD8
þ T
cell responses in chronic viral infections are characterized by
an increasing degree of functional impairment, and this
defect has been proposed as one reason for the incapability
of the host to clear the persisting infection.
In HIV-1 infection, numerous studies have described the
accumulation of functional impairments of virus-speciﬁc
CD8
þT cells from early to chronic stages of infection. Besides
a skewed maturation process from effector memory to
effector cells [8,11], signiﬁcant differences in the ability of
HIV-1–speciﬁc CD8
þ T cells to proliferate and to secrete
cytokines have been reported between patients with pro-
gressive versus nonprogressive HIV-1 disease [12–15]. Com-
parison of virus-speciﬁc CD8
þ T cell responses between HIV-
1–infected individuals with persistently low viral loads (non-
progressors) and HIV-1–infected individuals with ongoing
viremia (progressors) have furthermore suggested that ‘‘poly-
functional’’ CD8
þ T cells with the ability to mediate up to ﬁve
different effector functions (CD107a, interleukin [IL]-2,
tumor necrosis factor [TNF]-a,i n t e r f e r o n[ I F N ] - c,a n d
macrophage inﬂammatory protein [MIP]-1b) in response to
stimulation by antigen may form the basis of a more effective
CD8
þ T cell response [16,17]. Similarly, differences between
antigen-speciﬁc CD8
þ T cells from HIV-1 progressors and
nonprogressors with respect to up-regulation of programmed
death-1 (PD-1, also called CD279) [18–21] and down-
modulation of the IL-7 receptor in chronic viral infection
(CD127) [22,23] have been demonstrated. While PD-1 has
been described as a marker for activation and susceptibility
to apoptosis [24] and CD127 down-modulation as a marker
for a lack of transition into memory T cells [23], both markers
have been linked to the functional exhaustion of CD8
þT cells
[18,20,21,24,25].
Based on these recent studies suggesting that loss of
‘‘polyfunctional’’ virus-speciﬁc CD8
þ T cells and up-regula-
tion of PD-1 on those cells are correlates of immune failure in
chronic viral infection, we hypothesized that antigen persis-
tence directly affects the functionality of antigen-speciﬁc
CD8
þ T cells during the transition from acute to chronic
infection. We therefore used HIV-1 infection as a model of
chronic persistent viral infection to investigate the process of
exhaustion and dysfunction of virus-speciﬁc CD8
þ T cell
responses on the single-epitope level over time, starting in
primary infection.
Material and Methods
Participants
Longitudinal peripheral blood mononuclear cell (PBMC)
samples from 18 HIV-1–infected individuals with either acute
or early HIV-1 infection were investigated. Eleven individuals
with acute HIV-1 infection, as deﬁned by either a negative
HIV-1 p24 ELISA or an evolving HIV-1 Western blot (less
than three bands), and seven individuals with early HIV-1
infection, deﬁned as HIV-1 seroconversion within 6 mo prior
to study enrollment, were recruited from Massachusetts
General Hospital and the Fenway Community Health Center
in Boston, Massachusetts. Table 1 shows the clinical charac-
teristics of study participants. The respective institutional
review boards approved the present study, and each
participant provided written, informed consent for partic-
ipation in the study.
Peptides
Peptides corresponding to previously described HLA-
matched optimal CD8
þ T cell epitopes were used in this
study [26] and synthesized at the Massachusetts General
Hospital Peptide Synthesis Core Facility.
HLA Tissue Typing
High- and intermediate-resolution HLA class I typing was
performed by sequence-speciﬁc PCRs according to standard
procedures. DNA was extracted from PBMCs using Purgene
DNA Isolation Kit for blood (Gentra Systems).
Determination of HIV Gene Sequences and Viral Subtypes
HIV RNA was extracted from 500 ll of frozen plasma using
a guanidinium-based lysis buffer followed by isopropanol and
ethanol washes. A negative (PBS buffer) control was included
in each extraction run. HIV gag (codons 1–501, HXB2
nucleotides (nt) 789-2293), protease (codons 1–99, nt 2253–
2549), reverse transcriptase (codons 1–400, nt 2550–3749), env
gp160 (nt 6225–8795), and nef (codons 1–206; nt 8797–9414)
were ampliﬁed by nested RT-PCR using sequence-speciﬁc
primers. Ampliﬁed products were ‘‘bulk’’ sequenced in both
59 and 39 directions on an automated DNA sequencer. HIV
sequence data were analyzed using Sequencher (Genecodes).
Nucleotide mixtures were called if the height of the
secondary peak exceeded 30% of dominant peak height.
Sequence data were aligned to HIV-1 subtype B reference
strain HXB2 (GenBank [http://www.ncbi.nlm.nih.gov/sites/
entrez] accession no. K03455) using a modiﬁed NAP
algorithm [26,27], insertions stripped out, and alignments
visually inspected. Neighbor-joining phylogenetic trees were
constructed to guard against potential sample mixups or
contamination events, and to ensure that longitudinal
samples from the same participant clustered together, as
described [28].
Assessing Early and Late T Cell Responses by IFN-c
ELISPOT Assay
CD8
þ T cell responses were assessed by IFN-c ELISPOT at
the 2 mo time point after diagnosis with primary HIV-1
infection (6 10 d). PBMC were plated in 96-well polyvinyli-
dene diﬂuoride–backed plates (MAIP S45; Millipore) that had
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CD8
þ T Cell Functionalitybeen coated previously with 100 ll of an anti–IFN-c mAb 1-
D1k (2 lg/ml; Mabtech) overnight at 4 8C. Peptides were
added directly to the wells at a ﬁnal concentration of 14 lg/
ml. Cells were added to the wells at 50,000–100,000 cells/well.
The plates were incubated at 37 8C, 5% CO2 overnight (14–16
h) and then processed as described [29]. IFN-c–producing
cells were counted using the AID ELISPOT reader and are
expressed as spot-forming cells (SFCs) per 10
6 cells. The
number of speciﬁc IFN-c–secreting T cells was calculated by
subtracting the negative control value from the established
SFC count. The negative controls were always , 30 SFCs/10
6
input cells. A response was considered positive if . 55 SFC
per 10
6 and at least three times greater than mean back-
ground activity. The positive control consisted of incubation
of 100,000 PBMCs with phytohemagglutinin.
Assessing Functional Avidity of Epitope-Specific T Cells
Using Serial Peptide Dilutions
Functional avidity of epitope-speciﬁc CD8
þ T cells was
investigated by using serial 1:10 peptide titrations in an
ELISPOT assay and was deﬁned as peptide concentration that
resulted in 50% maximum (IC50) IFN-c production, as
described previously [30].
Assessing Antigen-Specific T Cell Function by
Multiparameter Flow Cytometry
Cryopreserved PBMCs of the 2 mo and following time
point used for ELISPOT assays (as described above) were
thawed, resuspended to 1–2 3 10
6 cells/ml in R10 media
(RPMI 1640 supplemented with 10% heat-inactivated FCS,
100 U/ml penicillin, 100 lg/ml streptomycin sulfate, 5.5 ml of
HEPES buffer; pH 7.2 6 0.2), and rested for 1–2 h at 37 8C;
5% CO2. PBMCs were then examined for viability by Trypan
blue exclusion (typically 80%–90% viable) and adjusted to 13
10
6 cells/ml. Co-stimulatory antibodies (CD28 and 49d, 1 lg/
ml; BD Biosciences) and CD107a-PE-Cy5 (BD Biosciences)
were added and the cells aliquoted at 1 ml to each tube
containing 2 lg/ml of each peptide. An unstimulated (R10
only) and a positive control (2 ll of phorbol-12-myristate-13-
acetate 1mg/ml and 1 ll of ionomycin 1 mg/ml [AG Scientiﬁc])
were included in each assay. Cells were incubated for 30 min
at 37 8C, 5% CO2, and monensin (Golgistop, 0.7 ll/ml; BD
Biosciences) and brefeldin A (10 lg/ml; Sigma-Aldrich) were
then added. Following a total incubation of 6 h, the cells were
washed with PBS and stained for intracellular amine groups
in order to discriminate between live and dead cells (blue
viability dye, Invitrogen). Cells were washed again and then
stained with anti-CD3-Paciﬁc blue (BD Biosciences), anti-
CD8-APC-Cy7 antibodies (BD Biosciences). Cells were then
ﬁxed in 1% paraformaldehyde (Fix Perm A), washed with
PBS, and then permeabilized (Fix Perm B solution) (Caltag
Laboratories). Cells were intracellularly stained using a panel
of Il-2-FITC (BD Biosciences), IFN-c-PE-Cy7 (BD Biosciences),
TNF-a-Alexa700 (BD Biosciences), and MIP-1b-PE (BD Bio-
sciences). Between 150,000 and 500,000 events were collected
per sample. All data were collected on a BD LSRII (BD
Biosciences) ﬂow cytometer and analyzed using FlowJo 8.3.3
software (TreeStar). Initial gating was on the lymphocyte
population and then used a forward scatter width (FSC-W)
versus height (FSC-H) plot to remove doublets (see Figure
1A). Subsequently, the events were gated through a side
scatter (SSC) versus blue viability dye (UV) and sequentially
gated on CD3
þ and CD8
þ events. Following identiﬁcation of
CD8
þ T cells, a gate was made for each respective function
using combinations that provided optimal separation. After
the gates for each function were created, we used the Boolean
gate platform to create the full array of possible combina-
tions, equating to 32 response patterns when testing ﬁve
functions. Data are reported after background correction
and the percent of epitope-speciﬁc CD8
þT cell responses had
to be at least .2-fold higher than background for individual
cytokines or CD107a before using the Boolean gate platform
to be considered as a positive response.
Assessing CD127 Frequency and PD-1 Expression on
Epitope-Specific (Tetramer-Positive) CD8
þ T Cells
Cryopreserved PBMCs were processed as described above.
Cells were then washed with PBS and stained for intracellular
amine groups in order to discriminate between live and dead
cells (blue viability dye, Invitrogen). After an additional wash
with PBS, PE-labeled HLA class I tetramers or pentamers
(Beckman-Coulter, NIH, Proimmune) refolded with the
Figure 1. Multiparameter Flow Cytometric Analysis of the Impact of Antiretroviral Therapy Initiation on the Functional Response Pattern of Antigen-
Specific CD8
þ T Cells
(A) Gating scheme for identification of multifunctional CD8
þ T cell responses. Single function gates were set based on negative control (unstimulated)
samples and were placed consistently across samples. Initial gating was on the lymphocyte population. Doublets were removed in a forward scatter
width (FSC-W) versus height (FSC-H) plot and live/dead discrimination was done subsequently with exclusion of high blue viability dye expression (UV).
Sequentially CD3
þ and CD8
þ events were defined and gates for each respective function using combinations that provided optimal separation were
made. After the gates for each function were created, we used the Boolean gate platform to create the full array of possible combinations, equating to
32 (2
5) response patterns when testing five functions. Shown here are the responses of patient Ac-160 to the HLA-B27-restricted epitope KK10 in p24
Gag. Data are reported after background correction.
(B) Representative multifunctional composition of epitope-specific CD8
þ T cell responses in an untreated patient identified during primary HIV-1
infection (Ac-177). Epitope-specific CD8
þ T cell responses against four HIV-1 epitopes were studied during primary (early) and chronic (late) HIV-1
infection in this patient. All 32 possible combinations of the five antigen-specific functions studied for each epitope are shown on the x-axis and the
contribution of each epitope-specific CD8
þ T cell population exhibiting the respective combination of functions to the total epitope-specific response
are indicated as bars. Responses are grouped and color-coded according to the number of functions (1¼yellow, 2¼cyan, 3¼green, 4¼blue, 5¼red).
Dark grey bars show the results from the early sample; light grey bars show the results from the later samples. The data are summarized by pie charts in
which each slice of the pie represents the fraction of the total epitope-specific response that consists of CD8
þ T cells with the respective number of
functions. Pie charts on the left represent the fraction of the respective epitope-specific CD8
þ T cell responses during primary HIV-1 infection (early),
while pie charts on the right represent the later time point (late).
(C) Representative multifunctional composition of epitope-specific CD8
þ T cell responses of a patient, who received HAART during primary HIV-1
infection (AC-85). Strategy of analysis and figure layout is same as described for (B). The functionality of epitope-specific CD8
þ T cell responses against
the HLA-B8-restricted epitope FL8 in Nef and HLA-A2-restricted epitope YI9 in RT remained stable or even slightly increased from a time point before
(early) to a time point after (late) antiretroviral treatment initiation.
doi:10.1371/journal.pmed.0050100.g001
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þT cell epitopes were added. Following 20 min
incubation at room temperature, cells were stained with the
surface antibodies anti-CD3-Paciﬁc blue (BD Biosciences),
anti-CD8-APC-Cy7 (BD Biosciences), anti-CD127-biotiny-
lated cascade yellow (BD Biosciences/Caltag, Invitrogen),
and anti-PD-1 Alexa 647 (Gordon Freeman) for 20 min and
after additional washing steps ﬁxed with 1% paraformalde-
hyde. Data collection and analysis was performed as described
above.
Statistical Analysis
Unless otherwise noted, all data were background-sub-
tracted and a lower threshold corresponding to at least twice
above background was built for individual cytokine, chemo-
kine, and CD107a expression in the ﬂow cytometry-based
experiments. Values below this threshold were set to 0. PD-1
expression was assessed by median ﬂuorescence intensity
(MFI). We used the general linear model to test for
differences between observations at the respective time
points, and two-way interaction effects were modeled to
assess differences between observation periods for different
groups. The standard errors of the estimate were adjusted for
clustering by participant. Statistical analyses were performed
using Graph Pad Prism 4.0, Excel (Microsoft Ofﬁce), and
STATA 9. A p-value below 0.05 (p , 0.05) was considered
statistically signiﬁcant.
Results
Influence of Antigen Persistence and Elimination on Virus-
Specific CD8
þ T Cell Function
Viral antigen has been associated with both the develop-
ment and expansion of virus-speciﬁc CD8
þ T cells during
acute infection and their functional impairment in the
setting of persistent antigenemia during chronic viral
infection. To determine the impact of antigen on the
functionality of virus-speciﬁc CD8
þ T cell responses, we
compared CD8
þ T cell responses directed against eight
optimal HIV-1 epitopes in seven patients identiﬁed during
primary HIV-1 infection before and after initiation of
treatment with highly active antiretroviral therapy (HAART),
as well as responses against 26 optimal HIV-1 epitopes in 11
patients with primary HIV-1 infection who remained un-
treated (Table 2). The median viral load before initiation of
HAART among untreated patients was lower (25,200 copies/
ml [range 1,760–188,000 copies/ml]) when compared to
treated patients (160,000 copies/ml [range 12,400–396,000]),
although this difference did not achieve statistical signiﬁ-
cance (p ¼ 0.12). Among untreated patients, viral loads
increased slightly over study follow-up (median of 30,300
copies/ml [1,112 – 427,000 copies/ml]), while viral load
dropped below the level of detection in all treated patients
at the follow-up time point (Table 1). Mean follow-up times
for untreated and treated patients were 282 and 141 d,
respectively.
A comprehensive functional proﬁle of the studied epitope-
speciﬁc CD8
þ T cells was assessed in all study participants at
the 2 mo time point (6 10 d) and follow-up time points by
multiparameter ﬂow cytometry using a panel quantifying ﬁve
different antigen-speciﬁc functions, including CD107a, a
marker for T cell degranulation, IFN-c, IL-2, TNF-a, and
MIP-1b. The bulk response of HIV-1–speciﬁc CD8
þ T cells
directed against the eight studied epitopes in the treatment
group decreased (average 6 SD: 2.3% 6 3.2% to 0.89% 6
1.0%, p ¼ 0.21) following initiation of HAART, as described
previously [31–34], but this decrease in HIV-1-speciﬁc CD8
þT
cell frequencies was not statistically signiﬁcant. In contrast,
the bulk antigen-speciﬁc CD8
þ T cell responses did not
change in the untreated group during the study period
(average 6 SD: 0.82% 6 1.34% to 0.72% 6 0.73%).
We next investigated the changes in the functional proﬁle
of HIV-1–speciﬁc CD8
þ T cells in the untreated and treated
groups, using the ﬁve functional readouts described above.
Gates for all ﬁve different functions were created (Figure 1A)
and the Boolean gate platform was used, as described [16], to
generate the full array of possible combinations, equating to
32 response patterns when testing ﬁve functions. Subse-
quently, the fraction of the total epitope-speciﬁc CD8
þT cells
able to respond to antigenic stimulation with one, two, three,
four, or ﬁve function(s), respectively, was calculated, as
described previously [17]. Initially, we longitudinally assessed
the functional qualities of virus-speciﬁc CD8
þ Tc e l l
responses in patients who did not receive any antiretroviral
treatment (Figure 1B). Even though all patients were studied
within 2 mo of presentation with primary HIV-1 infection,
the functionality of epitope-speciﬁc CD8
þ T cell responses
differed substantially among the patients. Interestingly, the
functionality of epitope-speciﬁc CD8
þ T cell responses
differed not only between patients but also substantially
within the same patient and ranged from monofunctional to
four-functional responses for different epitopes studied in
the same patient (Figure 1B).
Despite this variability, there was a similar pattern of
changes in virus-speciﬁc CD8
þ T cell functionality from early
to chronic HIV-1 infection in the patients who did not
receive antiretroviral treatment, as exempliﬁed for patient
Ac-177 (Figure 1B). The functional proﬁle of CD8
þ T cells
directed against the four HIV-1 epitopes studied in this
patient substantially changed over a study period of 163 d.
While the CD8
þ T cells against the HIV-1 epitopes
FLKEKGGL (B8-FL8) in Nef, YFPDWQNYT (A1-YT9) in
Nef, and FLGKIWPSHK (A2-FK10) in p15 Gag showed a
three- and four-functional response to antigenic stimulation
at the ﬁrst time point studied during primary infection, these
epitope-speciﬁc CD8
þ T cell responses became predomi-
nantly monofunctional at the time point studied 166 d later.
The functionality of the CD8
þ T cell response against the
HLA-B8-restricted epitope EIYKRWII (B8-EI8) in p24 Gag,
which consisted of up to four functions during primary
infection, also decreased, but less prominently compared to
the other three epitope-speciﬁc responses. There was no clear
pattern in the order by which individual CD8
þ Tc e l l
functions disappeared. However, TNF-a was never present
as a monofunctional response, in line with previous studies
describing the early loss of this effector function [1,35]. These
data indicate that the ability of CD8
þ T cells to respond to
antigenic stimulation with cytokine secretion and degranu-
lation differs between epitopes in the same patient, but
decreases from acute to chronic HIV-1 infection, resulting in
a predominantly monofunctional response toward the
chronic stage of infection in patients with persistent viral
replication.
In contrast to this overall reduction in the functional
proﬁle of epitope-speciﬁc CD8
þ T cells during untreated
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CD8
þ T cells in individuals who were treated with HAART
was largely maintained or even expanded, as shown in Figure
1C for patient Ac-85. CD8
þ T cell responses against the HLA-
A2–restricted epitope YTAFTIPSI (A2-YI9) in RT showed a
mainly mono- and dual-functional cytokine secreting proﬁle
at baseline, while responses against the HLA-B8-restricted
epitope in Nef FLKEKGGL (B8-FL8) were dominated by a
dual- to tri-functional responses (Figure 1C). In this patient,
viral load was suppressed below the level of detection by
HAART, and HIV-1–speciﬁc CD8
þ T cell responses were
again characterized after 141 days of antiretroviral treatment.
While the overall magnitude of the speciﬁc responses
declined, HIV-1–speciﬁc CD8
þ T cell responses maintained
or even slightly improved in their ability to secrete multiple
cytokines and chemokines for both epitopes, in contrast to
the substantial decrease in the functional repertoire observed
in untreated patient Ac-177.
We next compared for the entire group of untreated and
treated study patients the functional proﬁle of all epitope-
speciﬁc CD8
þ T cell responses detected at an early time point
before treatment initiation and a late time point after
treatment initiation or a respective time point in the
untreated group (Table 1). Each fraction of function was
calculated as a percentage of the total CD8
þT cell response as
described above. In the untreated patients, the functional
proﬁle of epitope-speciﬁc CD8
þ T cell responses decreased
over time, while the fraction of virus-speciﬁc CD8
þ T cells
with a single cytokine/chemokine function increased (Figure
2A and Table S1). In contrast, the functional proﬁle of
Table 2. Characteristics of Studied Epitopes
Group Patient Epitopes Sequence,
First Time
Point
Sequence,
Second
Time Point
Days Between
First and Second
Time Point
Days between
Last Detected
WT Sequence
and Assessment
of Second Time
Point
Antiretroviral
Therapy
Patients on HAART Ac-55 Cw8-AL9 (Nef) AVDLSHFLK — 100 n/a yes
Ac-76 Cw5-SL9 (Rev) SAEPVPLQL — 203 n/a yes
Ac-84 B18-FK10 (p24) FRDYVDRFYK — 95 n/a yes
Ac-85 A2-YI9 (RT) YTAFTIPSI — 141 n/a yes
B8-FL8 (Nef) FLKEKGGL — — n/a —
Ac-78 B8-WM8 (Nef) WPTVRERM — 126 n/a yes
Ac-153 B57-TW10 (p24) TSTLQEQIGW — 61 n/a yes
Ac-158 B7-GL9 (p24) GPKVKQWPL — 261 n/a yes
Average 141
Untreated Patients with no Epitope
Variant at Second Time Point
Ac-166 A11-ALK9 (Nef) AVDLSHFLK AVDLSHFLK 409 n/a no
Ac-211 B8-EI8 (p24) EIYKRWII EIYKRWII 350 n/a no
Cw7-KY11 (Nef) KRQDILDLWVY KRQDILDLWVY — n/a —
Ac-177 B8-FL8 (Nef) FLKEKGGL FLKEKGGL 163 n/a no
B8-EI8 (p24) EIYKRWII EIYKRWII — n/a —
A1-YT9 (Nef) FFPDWQNYT FFPDWQNYT — n/a —
A2-FK10 (p15) FLGKIWPSHK FLGKIWPSHK — n/a —
Ac-96 B8-FL8 (Nef) FLKEKGGL FLKEKGGL 364 n/a no
Ac-183 A1-YT9 (Nef) YFPDWQNYT YFPDWQNYT 215 n/a no
B44-AW11 (p24) AEQASQDVKNW AEQASQDVKNW — n/a —
Ac-98 A3-RK9 (p17) RLRQGGRKK RLRQGGRKK 511 n/a no
Average 335
Untreated Patients with Epitope
Variants at Second Time Point
Ac-166 B8-FL8 (Nef) FLKEKGGL FLRKEGGL 409 90 no
A1-QY9 (gp41) QRGWEVLKY LRGWEILKY — 90 —
Ac-211 A3-RK9 (p17) RLRPGGKKK RLRPGGKKR 350 206 no
B8-FL8 (Nef) FLKEKGGL FLKEQGGL — 83 —
Ac-183 A1-WH10 (Nef) WRFDSRLAHH WKFDSLLAHH 215 173 no
B27-KK10 (p24) KRWIIIGLNK KRWII[I/M]GLNK — 173 —
Ac-38 A3-RK9 (p17) RLRPGGKKK RLRPGGKKQ6 8 6 8 n o
Ac-98 Cw8-AL9 (Nef) AAVDLSHFL AA[F/L]DLSYFL 511 367 no
B35DL9 (gp120) DPNPQEVVL DP[N/S]PQEI[A/V]L — 186 —
Ac-83 A2-YI9 (RT) YTAFTIPSI YTAFTIPS[I/A/T/V] 182 182 no
B40-KL9 (Nef) KEKGGLEGL [K/R]EKGGLEGL — 182 —
B51-TI8 (RT) TAFTIPSI TAFTIPS[I/A/T/V] — 182 —
Ac-160 B27-KK10 (p24) KRWIIIGLNK KRWIIMGLNK 61 40 no
Ac-193 A3-RK9 (p17) RLRPGGKKK RLRPGGKKT 405 405 no
Ac-199 A2-SL9 (p17) SLYNTVATL SLYNTVAVL 330 330 no
Average 281 184
Variant amino acids within the epitope are indicated by underline. Mixed bases are indicated as [X/Y].
doi:10.1371/journal.pmed.0050100.t002
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þ T cells in treated study patients
remained stable or broadened (Figure 2B and Table S1). A
signiﬁcant (p , 0.05) two-way interaction effect was detected
between treatment and observation period, where the effect
of observation period was expected to produce opposite
effects by group. In this case, an appreciable increase of the
single cytokine/chemokine function was observed in un-
treated patients (Figure 2A), contrasting the decrease of the
monofunctional responses in the treated patients (Figure 2B,
p , 0.05). Similarly, the contribution of four-functional CD8
þ
T cell responses decreased in the untreated group, while it
slightly increased in the treated group (p , 0.05). In contrast
to the signiﬁcant changes in the functionality of HIV-1–
speciﬁc CD8
þ T cells in the presence or absence of HIV-1
antigen, CMV-, Flu-, or EBV-speciﬁc CD8
þ T cell functions
did not change signiﬁcantly over time (see Figure S1),
indicating that HIV-1 antigenemia itself was the driving
force for the qualitative changes in the HIV-1–speciﬁc CD8
þ
T cell functionality. The more restricted functional proﬁle of
CEF-speciﬁc CD8
þ T cell responses in our study compared to
a previous publication [16] might be due to the more
restrictive deﬁnition of a positive individual cytokine
response (twice above background) before Boolean gating
used here, and substantial difference in the clinical character-
istics of the study cohorts (primary versus chronic HIV-1
infection). Taken together, these longitudinal studies of HIV-
1–speciﬁc CD8
þ T cell functionality in individuals with
treated and untreated primary HIV-1 infection demonstrate
that the quality of an epitope-speciﬁc CD8
þ T cell response
remains stable or improves in the absence of antigen
following initiation of antiretroviral therapy but decreases
in the presence of persistent antigen.
Amino Acid Substitutions within the Targeted Epitope
Influence the Functional Ability of the Respective Epitope-
Specific CD8
þ T-Cell Response
The above data indicate that changes in the functional
proﬁle of HIV-1–speciﬁc CD8
þ T cells largely depend on the
presence or absence of antigen. Previous studies have
demonstrated the ability of HIV-1 to evade CD8
þ T cell–
mediated immune pressure by selection of escape variants,
where sequence mutations within targeted T cell epitopes can
have a signiﬁcant impact on the avidity of the interactions
between the TCR and the HLA class I–presented epitope [36–
38]. To investigate the impact of HIV-1 sequence variations
over time on the functional proﬁle of epitope-speciﬁc CD8
þ
T cells, we longitudinally sequenced plasma virus RNA of all
Figure 2. Loss of Epitope-Specific CD8
þ T Cell Functionality during Antigen Persistence
(A) Summary of fractions of epitope-specific CD8
þT cell responses with one, two, three, four, and five antigen-specific functions in 11 untreated patients
(nRx); (B) summary of fractions of eight epitope-specific CD8
þ T cell responses for seven patients before and after receiving antiretroviral therapy (Rx).
Frequencies of different combination of epitope-specific CD8
þT cell functions were quantified with Boolean gates using FlowJo software, and fractions
were calculated from total epitope-specific CD8
þT cell response. Each of the combination of epitope-specific functions (1–5) is shown separately before
(‘‘early’’) and after (‘‘late’’) antiretroviral treatment initiation for the treated study group (Rx) or for a corresponding early and late time point in the
untreated group (nRx), respectively. The monofunctional fraction of the HIV-1–specific CD8
þ T cell response increased significantly (p , 0.05) in
comparison to a decrease of the monofunctional fraction of the HIV-1–specific CD8
þT cell response in the treated group (*). In addition, the increase of
the four-functional fraction of the HIV-1–specific CD8
þT cell responses in the treated group was significant (p , 0.05) in comparison to the decrease of
the four-functional fraction in the untreated group (*). We used the general linear model to test two-way interaction effects between observation
period and group (nRx versus Rx) to calculate significance, and standard errors of the estimate were adjusted for clustering by patient.
doi:10.1371/journal.pmed.0050100.g002
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Among the 11 untreated patients, we identiﬁed 15 epitopes
that developed amino acid substitutions at the later time
point and, for comparison, 11 epitopes within the same
patients that remained conserved (Table 2).
As exempliﬁed for one untreated study patient in Figure
3A (Ac-211), the CD8
þ T cell response against the HLA-Cw7–
restricted epitope KRQDILDLWVY (Cw7-KY11) in Nef lost
the capability for a ‘‘polyfunctional’’ response and became
predominantly (64%) monofunctional (Figure 3A). Similarly,
the T cell responses against the HLA-B8-restricted epitopes
FLKEKGGL (B8-FL8) in Nef and EIYKRWII (B8-EI8) in p24
Gag included at the ﬁrst time point a mixture of CD8
þ T cells
able to exhibit up to three different functions following
antigenic stimulation, but became predominantly monofunc-
tional (75% and 95% respectively) at the later time point. In
contrast, the response against the HLA-A3–restricted epitope
RLRPGGKKK (A3-RK9) in p17 Gag increased from a 100%
monofunctional response to a dual- and triple-functional
response in the same patient. Sequence analysis within these
epitopes revealed a conservation of the sequences within the
Cw7-KY11 and B8-EI8 epitopes during the study period,
while the B8-FL8 and the A3-RK9 epitopes revealed amino
acid substitutions (A3-RK9 at position 9 from K to R, and B8-
FL8 at position 5 from K to Q; see Figure 3A and Table 2).
While the change from lysine to glutamine in B8-FL8 had no
signiﬁcant impact on the recognition by CD8
þT cells and was
recognized with comparable functional avidity to the wild-
type sequence, the K-to-R mutation in the A3-RK9 epitope
resulted in a much lower functional avidity, in line with
previous studies (see Figure 3B) [27]. These data in a single
individual suggest that sequence variations within a targeted
CD8
þ T cell epitope that lead to lost or reduced recognition
of the epitope can result in an increase in the functional
proﬁle of the respective epitope-speciﬁc CD8
þ Tc e l l
population.
We next extended this analysis to all the 15 epitopes that
developed amino acid substitutions and 11 epitopes that
remained conserved and compared changes in the functional
proﬁle of epitope-speciﬁc CD8
þ T cells between these two
groups (Figure 4; Table S1). Interestingly, the above described
decrease in the functional proﬁle of HIV-1–speciﬁc CD8
þ T
cells during untreated infection (Figure 2A), resulting in an
increase of monofunctional epitope-speciﬁc CD8
þT cells, was
much more pronounced and increased from 49% (95%
conﬁdence interval [CI] 27%–72%) to 76% (56%–95%)
(standard deviation [SD] of the effect size 0.71) when only
the 11 conserved epitopes were included and epitopes that
developed amino acid substitutions were excluded (Figure
4A). In striking contrast, CD8
þ T cells directed against the 15
HIV-1 epitopes that showed amino acid substitutions from
the ﬁrst to the second time point maintained a more diverse
functional proﬁle over time and the monofunctionality
remained stable or slightly decreased for responses directed
against escaped epitopes from 61% (95% CI 47%–75%) to
56% (42%–70%) (SD of the effect size 0.18). This change in
epitope-speciﬁc CD8
þ T cell functionality over time between
the two groups was signiﬁcant for changes in three-functional
responses (p , 0.05) and monofunctional responses (p ,
0.05). Functional avidity studies for several of these epitope-
speciﬁc CD8
þ T cell responses using serial dilutions of
peptides corresponding to either the wild-type or the variant
sequence of the respective epitope showed that the poly-
functionality of epitope-speciﬁc CD8
þ T cells increased
speciﬁcally for those epitopes that exhibited sequence
variations resulting in a substantial decrease in the functional
avidity (see Figure S2). The increase in epitope-speciﬁc CD8
þ
T cell functionality (deﬁned as the percent increase in
epitope-speciﬁc CD8
þ T cells with more than one function)
was furthermore signiﬁcantly correlated (R¼0.5, p¼0.025) to
changes in functional avidity (deﬁned as the change in the
IC50 for epitopes that developed sequence variations, see
Figure S2, and set to 0 for those epitopes that remained
conserved during the study period). These data demonstrate
that the functional quality of an epitope-speciﬁc CD8
þ T cell
response can be speciﬁcally modulated by sequence variation
within the targeted epitope, and is not a simple consequence
of overall viral load.
Decrease in PD-1 Expression on Epitope-Specific CD8
þ T
Cells Exhibiting a Change in the Viral Sequence of the
Targeted Epitope
Recently it has been shown that PD-1 expression on CD8
þT
cells is closely correlated with the functional exhaustion of
CD8
þ T cells in HIV-1–infected patients, and might serve as a
correlate of protective immunity [19,20,39]. Therefore, we
Figure 3. Representative Multifunctional Composition of Epitope-Specific CD8
þ T Cell Responses against Conserved Epitopes or Epitopes with
Sequence Variations in an Untreated Patient (Ac-211)
(A) Epitope-specific CD8
þ T cell responses against four HIV-1 epitopes were studied during primary and chronic HIV-1 infection in this patient (Ac-211).
All 32 possible combinations of the five antigen-specific functions studied for each epitope are shown on the x-axis, and the contribution of each
epitope-specific CD8
þ T cell population exhibiting the respective combination of functions to the total epitope-specific response are indicated as bars.
Responses are grouped and color-coded according to the number of functions (1¼yellow, 2¼cyan, 3¼green, 4¼blue, 5¼red). Dark grey bars show
the results from the early sample; light grey bars show the results from the later samples. The data are summarized by pie charts in which each slice of
the pie represents the fraction of the total epitope-specific response that consists of CD8
þT cells with the respective number of functions. Pie charts on
the left represent the fraction of the respective epitope-specific CD8
þ T cell responses during primary HIV-1 infection (early), while pie charts on the
right represent the later time point (late). Amino acid sequences of each studied epitope during the early and late time point are indicated next to each
graph. Amino acid substitutions within the epitope are highlighted in red shading. The functionality of the CD8
þ T cell responses against the epitopes
B8-EI9 in p24, B8-FL8 in Nef and Cw7-KY11 in Nef decreased to a primarily monofunctional composition, while the fraction of monofunctional epitope-
specific CD8
þT cells decreased, and two- and three functional responses increased, for the epitope A3-RK9 in p17. The amino acid sequence of the A3-
RK9 epitope displayed a substitution at the anchor residue position 9 from lysine (K) ! arginine (R).
(B) Comparison of the functional avidity of CD8
þT cells specific for two epitopes and their respective variants within the same individual (Ac-211). Upper
graph: Intraindividual comparison of the recognition of the B8-FL8 (Nef) wild type (WT) and the B8-FL8 K5Q variant measured by serial log dilution of
both peptides. IC50 was calculated and is indicated in the figure. The variant peptide was recognized with similar functional avidity at all concentrations
to the B8-FL8 WT peptide. Lower graph: Intraindividual comparison of the recognition of the A3-RK9 WT versus the A3-RK9 K9R variant was measured
by serial log dilutions of both peptides. IC50 was calculated and is indicated in the figure. The variant peptide was recognized with much lower
functional avidity at all concentrations than was the A3-RK9 WT peptide.
doi:10.1371/journal.pmed.0050100.g003
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interaction between CD8
þ T cells with their respective
epitope resulting from amino acid substitutions will also
affect the expression of PD-1 on those cells, indicating weaker
activation of these epitope-speciﬁc CD8
þ T cells. Sufﬁcient
specimens were available to longitudinally investigate CD8
þT
cell responses directed against ﬁve epitopes by tetramer
staining, which contained at the ﬁrst time point the wild-type
viral sequence but showed variation in the viral sequence at
the second time point that resulted in reduced recognition of
the epitope. CD8þ T cell responses directed against seven
epitopes in the same patients that remained conserved were
used as controls. While the MFI (6 standard deviation [SD]) of
PD-1 on epitope-speciﬁc tetramer-positive CD8
þ T cells
increased for the seven conserved epitopes over time (210
6 156 to 309 6 334; see Figure S3), PD-1 expression
signiﬁcantly decreased on the ﬁve epitope-speciﬁc CD8
þ T
cells that developed a sequence variation in the targeted
epitope (399 6 123 to 248 6 103, p ¼ 0.006 paired t-test)
(Figure 5), but was still higher than the PD-1 negative control.
In contrast, the expression of CD127 on epitope-speciﬁc cells
was very low, as described previously [22,40] and not
signiﬁcantly impacted by viral escape (unpublished data).
The reduction of PD-1 expression levels following escape
further support our previous results, which indicate a general
improvement of epitope-speciﬁc CD8
þ T cell functionality
and quality upon reduction of the speciﬁc antigen (epitope)
level that is independent of the overall level of viral
replication.
Discussion
The identiﬁcation of correlates of protective immunity in
HIV-1 infection has largely remained elusive [9]. Recent
studies have reported that effective virus-speciﬁc CD8
þT cells
display a ‘‘polyfunctional’’ capacity, including the ability to
secrete multiple cytokines and chemokines in response to
antigenic stimulation in HIV-1–infected individuals with
chronic long-term nonprogressive infection [16]. These data
suggest an important role for the ability of antigen-speciﬁc
CD8
þ T cells to secrete multiple cytokines/chemokines in the
control over viral replication. However, the preserved
functionality of HIV-1–speciﬁc CD8
þ T cells that is observed
in chronically infected individuals who control HIV-1 viremia
could represent either the cause of control over viral
replication or the consequence of low viremia. The longi-
tudinal studies in individuals identiﬁed during primary HIV-
1 infection presented here suggest that the functional proﬁle
of an epitope-speciﬁc CD8
þ T cell response is largely
Figure 4. Expansion of the Functional Profile of Epitope-Specific CD8
þ T Cells after the Emergence of Sequence Variations within the Respective
Targeted Epitopes
Fractions of epitope-specific CD8
þ T cell responses with one, two, three, four, and five antigen-specific functions for conserved epitopes (6 patients;
n¼11 epitopes) (A) are summarized in comparison to epitopes, which exhibited amino acid substitutions (9 patients; n¼15 epitopes). Frequencies of
different combination of cytokine production were assessed similarly to that in Figure 2A and 2B. Each of the functional profiles (1–5) are shown
separately before (‘‘early’’) or after (‘‘late’’) the development of an escape mutation in the targeted epitope or for CD8
þ T cell responses targeting a
conserved epitope at the same time points (‘‘early’’ or ‘‘late’’ respectively). While the monofunctional fraction increased in the targeted conserved
epitopes, it remained stable for the targeted epitopes developing a sequence variation. The interaction effect between group and period for conserved
and evolving epitopes was significant for three-functional responses (p , 0.05) (*) and for the monofunctional responses (p , 0.05) (*). We used the
general linear model to test two-way interaction effects between observation period and group (WT versus variant) to calculate significance, and
standard errors of the estimate were adjusted for clustering by patient.
doi:10.1371/journal.pmed.0050100.g004
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exposure, and is therefore mainly a consequence of viremia.
In this study we investigated whether the presence or
absence of antigen has an impact on the quality and
functionality of epitope-speciﬁc CD8
þ T cells during the
transition from acute to chronic HIV-1 infection. Our
longitudinal data demonstrate that HIV-1–speciﬁc CD8
þ T
cell responses directed against the individual epitopes studied
showed a very heterogeneous functional proﬁle, but more
‘‘polyfunctional’’ effector CD8
þ T cells were present in the
early phase than in later stages of HIV-1 infection. In the
presence of continued antigen stimulation during untreated
HIV-1 infection, the ability of HIV-1–speciﬁc CD8
þ T cells to
respond to antigenic stimulation with a combination of
degranulation and secretion of multiple cytokines and
chemokines was reduced, such that the later stages of
untreated HIV-1 infection were characterized by a predom-
inantly monofunctional cytokine or chemokine response
toward the same epitope. This result is in line with previous
studies indicating a sequential loss of effector functions of
virus-speciﬁc CD8
þ T cells, as was ﬁrst shown in the LCMV
model [5,6] but also reported in progressive chronic HIV-1
infection [12,35,41–43]. Further support for this selective
impairment of antigen-speciﬁc T cell function in chronic
infection is provided by the observation here that the loss of
functionality was restricted to HIV-1–speciﬁc CD8
þ T cells,
whereas no signiﬁcant changes occurred in the functionality
of CD8
þ T cell responses toward EBV, CMV, and inﬂuenza
antigens in the same participants. This observation suggests
that the impairment of a functional HIV-1–speciﬁc CD8
þ T
cell response during the transition from acute to chronic
infection likely represents the consequence of ongoing
speciﬁc antigenic stimulation. In line with this model, the
loss of functionality from acute to chronic HIV-1 infection
was arrested or even reversed in patients receiving antire-
troviral treatment, resulting in a general reduction of antigen
as shown previously [44,45]. Although the total number of
HIV-1–speciﬁc CD8
þ T cells decreased with antiretroviral
treatment, the ability of the remaining individual epitope-
speciﬁc CD8
þ T cells to secrete multiple cytokines/chemo-
kines in response to stimulation was maintained or increased
for HIV-1–speciﬁc responses, indicating that the functional
impairment of antigen-speciﬁc CD8þ T cells is dynamic and
can be partially restored.
To more precisely investigate the impact of antigen on the
functionality of CD8
þ T cells, we longitudinally studied
epitope-speciﬁc CD8
þ T cell responses directed against
conserved and escaping CTL epitopes in the same study
participant. This approach allowed us to directly compare,
within the same study participant, epitope-speciﬁc CD8
þ T
cell populations that were continuously driven by antigen
(conserved CTL epitopes) to those, where the speciﬁc antigen/
epitope evaded by sequence variation (escaped CTL epito-
pes). In line with the above data, studies of the epitope-
speciﬁc CD8
þ T cells directed against conserved epitopes
revealed a reduction in the functional proﬁle of these
continuously activated CD8
þ T cells. In contrast, epitope-
speciﬁc CD8
þ T cells regained functional capacities toward
the original ‘‘wild-type’’ epitope following the development
of sequence variations, and also signiﬁcantly down-regulated
the expression of PD-1, a marker of activation and exhaustion
of T cell responses. The biphasic pattern of the decrease of
PD-1 expression (Figure 5) suggests that PD-1-positive
epitope-speciﬁc CD8
þ T cell responses that are highly
exhausted either become apoptotic and die, while PD-1
low
epitope-speciﬁc CD8
þ T cell subsets expand following CTL
escape, or that PD-1
high cells are partially down-regulating
PD-1 expression on the cell surface. Similar ﬁndings were
recently reported in SIV-infected macaques, in which PD-1
expression gradually declined on CD8
þ T cells speciﬁc for
SIV-derived epitopes that had undergone mutational escape,
Figure 5. Reduction in PD-1 Expression on Epitope-Specific CD8
þ T Cells after Sequence Evolution in the Respective Epitopes
Primary flow data (for the HLA-A3-restricted epitope A3-RK9 in p17 Gag [left]) and combined data for five individuals (right) for PD-1 expression on
epitope-specific CD8
þ T cells before (‘‘WT–early’’) and after (‘‘variant–late’’) the selection of amino acid substitutions within the targeted epitopes are
shown. PD-1 is expressed as MFI on tetramer-positive CD8
þT cells. In the graph on the left, data from the early time point are shown by the black tracing,
while data for the late time point are shown by grey shading. A fluorescent minus one control is shown in comparison for both stainings. In the graph on
the right, grey lines represent changes within patients between time periods (‘‘WT,’’ early; ‘‘variant,’’ late); the black line represents the median PD-1
expression change on all five studied tetramer-positive CD8
þT cell populations between time periods. The decrease of the PD-1 expression on tetramer-
positive CD8
þ T cells before and after the development of sequence variations within epitopes was statistically significant (p ¼ 0.006; paired t-test).
doi:10.1371/journal.pmed.0050100.g005
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high expressing CD8
þ T cell were highly susceptible
to cell death [24].
Additional analysis of the functional avidity of CD8
þT cells
in response to peptides corresponding to the wild-type
epitope and the escape variant furthermore showed that
the functional proﬁle of epitope-speciﬁc CD8
þ T cells was
restored only under conditions in which the selected epitope
variant resulted in poor recognition. Thus, changes in the
functional proﬁle of CD8
þ T cells and the expression levels of
PD-1 can serve as strong indicators of whether a sequence
variation detected in a targeted viral epitope truly resulted in
reduced recognition by CD8
þ T cells. These studies compar-
ing the functionality of continuously activated and ‘‘escaped’’
CD8
þ T cell responses directed against the same pathogen
clearly highlights the dominant role of antigen persistence on
T cell functionality. This observation demonstrating a direct
link between the sequence evolution of a targeted epitope
and the ‘‘functionality’’ of the ex vivo response furthermore
emphasizes the necessity for the concomitant evaluation of
autologous viral sequences in studies aimed at correlating
CD8
þ T cell function, including PD-1 expression, with
markers of HIV-1 disease progression.
Overall, these data support a model in which antigen-
speciﬁc CD8
þ T cell function in chronic HIV-1 infection, as
deﬁned by the ability of epitope-speciﬁc CD8
þ T cells to
activate multiple functional pathways ex vivo following
stimulation, is largely deﬁned by the previous history of in
vivo antigenic stimulation. Similarly, these data support a
model in which continued recognition of speciﬁc antigen is
one of the major forces driving the functional impairment of
virus-speciﬁc CD8
þ T cells during chronic persistent in-
fections. Importantly, this study underscores the relevance of
evaluating autologous viral sequences when interpreting data
on the functionality of virus-speciﬁc immune responses.
Supporting Information
Figure S1. Preservation of the Functional Proﬁle of CD8
þ T Cell
Response towards CMV, EBV, or Inﬂuenza Indicate Important Role
of Antigen Load in Determining the Quality of CD8
þ Responses
Summary of fractions of CMV-, EBV-, or inﬂuenza-speciﬁc CD8
þ T
cell responses with one, two, three, four, and ﬁve antigen-speciﬁc
functions in eight untreated patients (three did not have a detectable
response) (A) and seven patients starting antiretroviral therapy (B).
Data are shown before (‘‘early’’)a n da f t e r( ‘‘late’’)r e c e i v i n g
antiretroviral therapy or a corresponding early (‘‘early) or late
(‘‘late’’) time point for untreated patients. Frequencies of different
combinations of epitope-speciﬁc CD8
þ Tc e l lf u n c t i o n sw e r e
quantiﬁed with Boolean gates using FlowJo software and fractions
were calculated from total epitope-speciﬁc CD8
þ T cell responses.
Each of the functional proﬁles (1–5) are shown separately before and
after antiretroviral treatment initiation for the treated study group
or for a corresponding early and late time point in the untreated
group, respectively. The functional proﬁle of the EBV-, CMV-, and
inﬂuenza-speciﬁc CD8
þT cell responses at the ﬁrst time point showed
a large percentage of dual-, triple-, and quadruple-functional
responses, did not differ between the treated and the untreated
groups, and did not change over time in the treated and the
untreated groups. None of the interaction effects between period and
treatment group reached signiﬁcance for any of the outcomes (1–5
functions).
Found at doi:10.1371/journal.pmed.0050100.sg001 (102 KB PPT).
Figure S2. Serial Peptide Titration Curves Comparing Recognition of
Peptides Corresponding to Wild-Type Sequences and to Evolving
Variants Identiﬁed by Sequencing of the Autologous Virus by
Epitope-Speciﬁc CD8
þ T Cells over Time in the Indicated Individuals
Peptide concentrations are shown in micrograms per milliliter. The
monofunctional fraction of epitope-speciﬁc CD8
þ T cells decreased
and the multifunctional fraction increased in cases in which the IC50
of the variant epitope showed a substantial decrease. The corre-
sponding monofunctional fraction for each epitope-speciﬁc CD8
þ T
cell response changed as follows: B51-TI8 (RT) 23.8% to 37.8%; Cw8
AL9 (Nef) 68.8% to 76%; A3-RK9 (p17) 68.2% to 21.2%; B27-KK10
(p24) 98.3% to 62.7%; A2-SL9 (p17) 55% to 76%; B27-KK10 (p24)
42.5% to 19.5%.
Found at doi:10.1371/journal.pmed.0050100.sg002 (100 KB PPT).
Figure S3. Changes of PD-1 Expression on Epitope-Speciﬁc CD8
þ T
Cells Directed against Conserved Epitopes at an Early and Late Time
Point
Displayed is the MFI of different epitope-speciﬁc (tetramerþ) CD8
þT
cells. The graphs illustrate changes of the PD-1 MFI of all investigated
tetramer-positive CD8
þT cells directed against conserved epitopes at
an early and late time point. The median of PD-1 expression on all
seven tetramer-positive CD8
þT cells is shown in bold. The increase of
the PD-1 expression on tetramer-positive CD8
þT cells at an early and
late time point did not reach statistical signiﬁcant (p ¼ 0.07 paired t-
test).
Found at doi:10.1371/journal.pmed.0050100.sg003 (61 KB PPT).
Table S1. Polyfunctional Proﬁle of Each Individual Epitope Tested
Found at doi:10.1371/journal.pmed.0050100.st001 (29 KB XLS).
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þ T Cell FunctionalityEditors’ Summary
Background. Viruses are small infectious agents responsible for many
human diseases, including acquired immunodeficiency syndrome (AIDS).
Like other viruses, the human immunodeficiency virus 1 (HIV-1; the cause
of AIDS) enters human cells and uses the cellular machinery to replicate
before bursting out of its temporary home. During the initial stage of HIV
infection, a particular group of cells in the human immune system, CD8
þ
T cells, are thought to be important in controlling the level of the virus.
These immune system cells recognize pieces of viral protein called
antigens displayed on the surface of infected cells; different subsets of
CD8
þ T cells recognize different antigens. When a CD8
þ T cell recognizes
its specific antigen (or more accurately, a small part of the antigen called
an ‘‘epitope’’), it releases cytotoxins (which kill the infected cells) and
cytokines, proteins that stimulate CD8
þ T cell proliferation and activate
other parts of the immune system. With many viruses, when a person
first becomes infected (an acute viral infection), antigen-specific CD8
þ T
cells completely clear the infection. But with HIV-1 and some other
viruses, these cells do not manage to remove all the viruses from the
body and a chronic (long-term) infection develops, during which the
immune system is constantly exposed to viral antigen.
Why Was This Study Done? In HIV-1 infections (and other chronic viral
infections), virus-specific CD8
þ T cells lose their ability to proliferate, to
make cytokines, and to kill infected cells as patients progress to the long-
term stages of infection. That is, the virus-specific CD8
þ T cells gradually
lose their ‘‘effector’’ functions and become functionally impaired or
‘‘exhausted.’’ ‘‘Polyfunctional’’ CD8
þ T cells (those that release multiple
cytokines in response to antigen) are believed to be essential for an
effective CD8
þ T cell response, so scientists trying to develop HIV-1
vaccines would like to stimulate the production of this type of cell. To do
this they need to understand why these polyfunctional cells are lost
during chronic infections. Is their loss the cause or the result of viral
persistence? In other words, does the constant presence of viral antigen
lead to the exhaustion of CD8
þ T cells during chronic HIV infection? In
this study, the researchers investigate this question by looking at the
polyfunctionality of CD8
þ cells responding to several different viral
epitopes at various times during HIV-1 infection, starting very early after
infection with HIV-1 had occurred.
What Did the Researchers Do and Find? The researchers enrolled 18
patients recently infected with HIV-1 and analyzed their CD8
þ T cell
responses to specific epitopes at various times after enrollment using a
technique called flow cytometry. They found that the epitope-specific
CD8
þ cells produced several effector proteins after antigen stimulation
during the initial stage of HIV-1 infection, but lost their polyfunctionality
in the face of persistent viral infection. The CD8
þ T cells also increased
their production of programmed death 1 (PD-1), a protein that has been
shown to be associated with the functional impairment of CD8
þ T cells.
Some of the patients began antiretroviral therapy during the study, and
the researchers found that this treatment, which reduced the viral load,
reversed CD8
þ T cell exhaustion. Finally, the appearance in the patients’
blood of viruses that had made changes in the specific epitopes
recognized by the CD8
þ T cells to avoid being killed by these cells, also
reversed the exhaustion of the T cells recognizing these particular
epitopes.
What Do These Findings Mean? These findings suggest that the
constant presence of HIV-1 antigen causes the functional impairment of
virus-specific CD8
þ T cell responses during chronic HIV-1 infections.
Treatment with antiretroviral drugs reversed this functional impairment
by reducing the amount of antigen in the patients. Similarly, the
appearance of viruses with altered epitopes, which effectively reduced
the amount of antigen recognized by those epitope-specific CD8
þT cells
without reducing the viral load, also reversed T cell exhaustion. These
results would not have been seen if the functional impairment of CD8
þ
cells were the cause rather than the result of antigen persistence. By
providing new insights into how the T cell response to viruses evolves
during persistent viral infections, these findings should help in the
design of vaccines against HIV and other viruses that cause chronic viral
infections.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050100.
  Read a related PLoS Medicine Research in Translation article
  Learn more from the researchers’ Web site, the Partners AIDS Research
Center
  Wikipedia has a page on cytotoxic T cells (note that Wikipedia is a free
online encyclopedia that anyone can edit; available in several
languages)
  Information is available from the US National Institute of Allergy and
Infectious Diseases on HIV infection and AIDS
  HIV InSite has comprehensive information on all aspects of HIV/AIDS,
including a detailed article on the immunopathogenesis of HIV
infection
  NAM, a UK registered charity, provides information about all aspects of
HIV and AIDS, including a fact sheet on the stages of HIV infection and
on the immune response to HIV
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